These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

210 related articles for article (PubMed ID: 35346067)

  • 1. Efficacy and predictor of anti-TNFα agents in patients with intestinal Behçet's disease.
    Miyazaki H; Watanabe D; Okamoto N; Tokunaga E; Ku Y; Takenaka H; Hoshi N; Ooi M; Kodama Y
    BMC Gastroenterol; 2022 Mar; 22(1):149. PubMed ID: 35346067
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Real-world efficacy of adalimumab and infliximab for refractory intestinal Behçet's disease.
    Sugimura N; Mizoshita T; Sugiyama T; Togawa S; Miyaki T; Suzuki T; Tanida S; Kataoka H; Sasaki M
    Dig Liver Dis; 2019 Jul; 51(7):967-971. PubMed ID: 30872086
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-Term Outcomes and Predictors of Sustained Response in Patients with Intestinal Behcet's Disease Treated with Infliximab.
    Zou J; Ji DN; Cai JF; Guan JL; Bao ZJ
    Dig Dis Sci; 2017 Feb; 62(2):441-447. PubMed ID: 28044230
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Anti-TNF-α agents for refractory intestinal Behçet's disease: case series and meta-analysis.
    Zhan S; Liu C; Li N; Li T; Tian Z; Zhao M; Wu D; Chen M; Zeng Z; Zhuang X
    Therap Adv Gastroenterol; 2022; 15():17562848221116666. PubMed ID: 36082178
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and Safety of Anti-Tumor Necrosis Factor-Alpha Agents for Patients with Intestinal Behcet's Disease: A Systematic Review and Meta-Analysis.
    Zhang Q; Ma C; Dong R; Xiang W; Li M; Ma Z; Yang Q
    Yonsei Med J; 2022 Feb; 63(2):148-157. PubMed ID: 35083900
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Risk Factors for Surgery in Patients with Intestinal Behçet's Disease During Anti-Tumor Necrosis Factor-Alpha Therapy.
    Han SJ; Kang EA; Park J; Park SJ; Park JJ; Kim TI; Kim WH; Cheon JH
    Yonsei Med J; 2023 Feb; 64(2):111-116. PubMed ID: 36719018
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The efficacy and safety of anti-tumor necrosis factor agents in the treatment of intestinal Behcet's disease, a systematic review and meta-analysis.
    Zhang M; Liu J; Liu T; Han W; Bai X; Ruan G; Lv H; Shu H; Li Y; Li J; Tan B; Zheng W; Xu H; Zheng W; Yang H; Qian J
    J Gastroenterol Hepatol; 2022 Apr; 37(4):608-619. PubMed ID: 34894004
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A case of intestinal Behçet's disease treated with infliximab monotherapy who successfully maintained clinical remission and complete mucosal healing for six years.
    Maruyama Y; Hisamatsu T; Matsuoka K; Naganuma M; Inoue N; Ogata H; Iwao Y; Kanai T; Hibi T
    Intern Med; 2012; 51(16):2125-9. PubMed ID: 22892489
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Remission induction, maintenance, and endoscopic outcome with oral 5-aminosalicylic acid in intestinal Behçet's disease.
    Kinoshita H; Nishioka H; Ikeda A; Ikoma K; Sameshima Y; Ohi H; Tatsuno M; Kouyama J; Kawamoto C; Mitsui T; Tamura Y; Hashimoto Y; Nishio M; Ogashiwa T; Saigusa Y; Maeda S; Kimura H; Kunisaki R; Koike K
    J Gastroenterol Hepatol; 2019 Nov; 34(11):1929-1939. PubMed ID: 31017728
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparative study of corticosteroid monotherapy, and TNF inhibitors with or without corticosteroid in patients with refractory entero-Behcet's disease.
    Miyagawa I; Nakano K; Iwata S; Nakayamada S; Saito K; Hanami K; Fukuyo S; Kubo S; Kawabe A; Miyazaki Y; Tanaka Y
    Arthritis Res Ther; 2019 Jun; 21(1):151. PubMed ID: 31228955
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mucosal Healing at 14 Weeks Predicts better Outcome in Low-dose Infliximab Treatment for Chinese Patients with Active Intestinal Behcet's Disease.
    Zou J; Ji DN; Shen Y; Guan JL; Zheng SB
    Ann Clin Lab Sci; 2017 Mar; 47(2):171-177. PubMed ID: 28442519
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy of TNFα inhibitors for refractory vascular Behçet's disease: A multicenter observational study of 27 patients and a review of the literature.
    Aksoy A; Yazici A; Omma A; Cefle A; Onen F; Tasdemir U; Ergun T; Direskeneli H; Alibaz-Oner F
    Int J Rheum Dis; 2020 Feb; 23(2):256-261. PubMed ID: 31976619
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effectiveness and safety of adalimumab in patients with intestinal Behçet's disease: a real-world prospective observational study in South Korea.
    Yu J; Shin SJ; Park YJ; Kim HW; Lee BI; Ye BD; Kim GT; Kim SK; Kim JS; Kim YH; Jeong S; Cheon JH
    BMC Gastroenterol; 2023 Dec; 23(1):449. PubMed ID: 38114956
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Brief Report: Drug-Free Long-Term Remission in Severe Behçet's Disease Following Withdrawal of Successful Anti-Tumor Necrosis Factor Treatment.
    Sfikakis PP; Arida A; Panopoulos S; Fragiadaki K; Pentazos G; Laskari K; Tektonidou M; Markomichelakis N
    Arthritis Rheumatol; 2017 Dec; 69(12):2380-2385. PubMed ID: 28834393
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Anti-Tumor Necrosis Factor Therapy in Intestinal Behçet's Disease.
    Park J; Cheon JH
    Gut Liver; 2018 Nov; 12(6):623-632. PubMed ID: 29788675
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy of anti-TNF alpha in severe and refractory major vessel involvement of Behcet's disease: A multicenter observational study of 18 patients.
    Desbois AC; Biard L; Addimanda O; Lambert M; Hachulla E; Launay D; Ackermann F; Pérard L; Hot A; Maurier F; Mausservey C; Bernard F; Noel N; Alric L; Mirault T; Cohen F; Boussouar S; Resche-Rigon M; Cacoub P; Saadoun D
    Clin Immunol; 2018 Dec; 197():54-59. PubMed ID: 30125675
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-term clinical outcomes of intestinal Behçet's disease: A 30-year cohort study at a tertiary hospital in South Korea.
    Park J; Park SJ; Park JJ; Kim TI; Cheon JH
    J Gastroenterol Hepatol; 2023 Mar; 38(3):386-392. PubMed ID: 36346041
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Intestinal Behçet's disease appearing during treatment with adalimumab in a patient with ankylosing spondylitis.
    Chung SH; Park SJ; Hong SP; Cheon JH; Kim TI; Kim WH
    World J Gastroenterol; 2013 Aug; 19(32):5389-92. PubMed ID: 23983446
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Management of severe complications in Behçet's disease with TNF inhibitors.
    Desbois AC; Vallet H; Domont F; Comarmond C; Cacoub P; Saadoun D
    Expert Opin Biol Ther; 2017 Jul; 17(7):853-859. PubMed ID: 28503960
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Successful treatment of a refractory intestinal Behcet's disease with an oncology history by Vedolizumab: a case report and literature review.
    Li R; Li X; Zhou H; Shi Y; Wang F; Wu T; Liang J
    Front Immunol; 2023; 14():1205046. PubMed ID: 37287984
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.